ABCL Q2 2022 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$46M+66.1% YoY

Gross Profit

$41M88.7% margin

Operating Income

-$8M-18.3% margin

Net Income

-$7M-14.8% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

-85.5%

Cash Flow

Operating Cash Flow

$272M

Free Cash Flow

$240M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$381M

Stockholders' Equity

$1.2B

Cash & Equivalents

$791M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$46M	$28M	+66.1%
Gross Profit	$41M	$24M	+69.4%
Operating Income	-$8M	-$7M	-19.4%
Net Income	-$7M	-$2M	-192.1%

Revenue Segments

Royalty

$33M72%

Research Fees

$13M27%

License

$147,0000%